|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 22, No 15 (August 1), 2004: pp. 3039-3045 © 2004 American Society of Clinical Oncology. DOI: 10.1200/JCO.2004.08.177 Ongoing Monoclonal B-Cell Proliferation Is Not Common in Gastric B-Cell Lymphoma After Combined RadiochemotherapyFrom the Departments of Internal Medicine, Hematology, Oncology, and Immunology, Hospital of the Philipps-University, Marburg; Department of Hematology, St Georg Hospital, Hamburg; Institute for Hematopathology, University of Kiel, Kiel; Institute for Pathology, University of Würzburg, Würzburg; and Institute for Pathology, Hospital Bayreuth, Bayreuth, Germany Address reprint requests to Andreas Neubauer, MD, Hospital of Philipps University, Department of Hematology, Oncology and Immunology, Baldinger Straße, 35033 Marburg, Germany; e-mail: neubauer{at}mailer.uni-marburg.de
PURPOSE: Gastric marginal-zone B-cell lymphoma (MZBCL) of the mucosa-associated lymphoid tissue (MALT) is associated with chronic Helicobacter pylori gastritis. Stable complete remission (CR) can be induced by H pylori eradication. Whether this is paralleled by cure of the lymphoma remains unclear. Persisting monoclonal bands for immunoglobulin heavy chain variable region (VH) representing the lymphoma clone have been described in up to 50% of patients in CR. This retrospective study investigated whether this phenomenon also occurs after radiochemotherapy. PATIENTS AND METHODS: Biopsy samples of 20 patients receiving chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone and irradiation were analyzed before and after therapy. Study patients had Ann Arbor stage I/II primary gastric cancer, including four cases of MZBCL of MALT type, 12 cases of diffuse large-cell lymphomas (DLCL), and four cases of mixed MALT type/DLCL. Polymerase chain reaction (PCR) for VH rearrangement was performed. Monoclonal PCR products were cloned and sequenced. RESULTS: Fourteen of 20 patients had a monoclonal or oligoclonal band distribution at diagnosis converted into polyclonal pattern after radiochemotherapy. Of the remaining six patients, two were lost to follow-up. One patient did not respond and died of progressive disease. PCR in this patient showed persistent B-cell clonality. In three patients, the initial PCR showed a polyclonal pattern and thus could not be evaluated during follow-up. CONCLUSION: In contrast with H pylori eradication alone, radiochemotherapy results in clearing of monoclonal cells during follow-up. This may result in better elimination of residual lymphoma cells. Further study is needed to determine whether this translates into lower risk of relapse.
Lymphomas arising from the mucosa-associated lymphoid tissue (MALT) have been regarded as a special entity, both clinically and biologically.1 They are typically found in organs that are primarily free of lymphoid tissue, like the salivary glands or the stomach. The acquisition of lymphoid tissue in these organs is caused by an infection or an autoimmune reaction and is a prerequisite for MALT lymphoma development. The strong association between gastric marginal-zone B-cell lymphomas (MZBCL) of MALT type and a chronic infection with Helicobacter pylori has been recognized.2 The lymphoma cell-specific immunoglobulin receptor is directed against auto-antigens of the gastric mucosa.3 Hussel et al4 showed convincingly that the proliferation of MALT lymphoma B cells in vitro depends on H pylorispecific T cells. Thus the proliferation of MALT lymphoma cells does not seem to be autonomous. On the contrary, the stimulation of a possibly autoimmune clonal B cell on the background of reactive inflammatory infiltration can be responsible for the tumor initiation. The hypothesis of a still controlled although malignant behavior of MALT lymphomas is supported by the clinical course of early low-grade MALT lymphoma. In keeping with this observation, Wotherspoon et al5 reported complete regressions of low-grade gastric MALT lymphomas after H pylori eradication therapy. These data were corroborated in larger cohorts by others.6-10 In longer follow-up studies, remissions were reported to be stable.10-12 The analysis of the rearranged variable region (VH) of the immunoglobulin heavy chain gene by means of polymerase chain reaction (PCR) can be used as a marker for the monoclonal proliferation of B-lymphoma cells.13 Furthermore, the sequence analysis of the characteristic immunoglobulin heavy chain gives insight into the lymphoma biology. The finding of somatic hypermutations indicates the postgerminal center origin of low-grade MALT lymphoma cells.14,15 Concomitant to the clinical evaluation after H pylori eradication in low-grade gastric MALT lymphoma, several study groups carried out analysis of the immunoglobulin heavy chain during follow-up. In up to 50% of patients, a persisting monoclonal PCR band was observed, although a histologic complete remission was diagnosed.9-11,16 Whether this observation points to a higher relapse risk because of quiescent lymphoma cells in the gastric mucosa remains unclear. Possibly the cure of H pylori infection induces remission of early low-grade MALT lymphomas by withdrawing the stimulating antigen but does not lead to a complete eradication of the lymphoma cells in these PCR-positive patients. In addition, sequence analysis of samples with persisting monoclonal PCR bands showed ongoing somatic hypermutations during follow-up.12 This was interpreted as a sign of antigen stimulation and antigen selection after cure of H pylori infection (ie, that the proliferation of lymphoma cells seems to be antigen-dependent).12,15 In this study, we examined whether the persistence of monoclonal bands is a common finding after treatment of gastric lymphomas. We therefore analyzed samples of patients with gastric B-cell non-Hodgkin's lymphoma (NHL) and who were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)based chemotherapy and irradiation.17
Patients Biopsy specimens from 20 retrospective patients suffering from gastric B-cell lymphoma were investigated. Diagnosis was made by one of the reference pathologists (R.P., M.S., H.K.M.-H.) by standard procedures as described previously.16 In four patients, an MZBCL of MALT type was diagnosed. Twelve patients suffered from a diffuse large B-cell lymphoma (DLCL). An MZBCL with portions of a DLCL was diagnosed in four patients. Median patient age was 58 years (range, 28 to 77 years). A summary of patient characteristics is included in Table 1.
Patients were treated between 1993 and 1996. All patients received multiple cycles of polychemotherapy with consecutive irradiation. Details of therapy are listed in Table 1. A CHOP-based chemotherapy regimen was used, containing cyclophosphamide 750 mg/m2 administered intravenously (IV) on day 1, vincristine 2 mg IV on day 1, doxorubicin 50 mg/m2 IV on day 1, and prednisone 100 mg administered orally on days 1 through 5. One patient had received, in addition to five cycles of CHOP, two cycles of chemotherapy with cyclophosphamide, epirubicin, vinblastine, and prednisone before irradiation.
DNA Extraction
PCR for the Rearranged Immunoglobulin Heavy Chain VH and Genescan Analysis
Cloning of Monoclonal PCR Products PCR samples, which showed monoclonal or biclonal bands in the Genescan analysis, were cloned and sequenced as described previously.12 In brief, the PCR product of the expected length was purified on an agarose gel using the QiaExII Kit (Qiagen) as recommended by the manufacturer. The extracted DNA was ligated in a pCR 2.1 TOPO vector using the TA-Cloning Kit (Invitrogen, Groningen, Netherlands). These plasmids were used for transformation of competent Escherichia coli cells, which were plated onto ampicillin-containing Luria Bertani culture plates. Bacteria colonies with successfully transformed, insert-carrying plasmids were recognized by blue-white screening and cultivated overnight in Luria Bertani soluble medium. The plasmid DNA was isolated using the Qia Miniprep Kit (Qiagen).
Sequencing
Clinical Data Nineteen of 20 patients received the scheduled CHOP-based chemotherapy. In one case, five cycles of CHOP were followed by two cycles of chemotherapy with cyclophosphamide, epirubicin, vinblastine, and prednisone. Chemotherapy was combined with irradiation in 18 patients. One patient (patient 9) refused radiation therapy. Patient 19 experienced relapse at the beginning of irradiation therapy and thus did not receive irradiation. Radiation was discontinued; the patient left the country and was lost to follow-up. Although data were obtained retrospectively, we carried out an intent-to-treat analysis on all patients and evaluated all patients further. Eighteen of 20 patients achieved a complete remission (CR). Patient 5 achieved a partial remission and was lost to follow-up. Patient 20 did not respond to treatment and died of general tumor progression. Two of 18 patients experienced relapse. In addition to patient 19 mentioned above, one patient (patient 14) experienced relapse 2 years after obtaining CR with a lymphoma in the ileum and involvement of local lymph nodes. The stomach was not investigated at this time. After surgery and 13 additional cycles of monotherapy with cyclophosphamide, no lymphoma activity has been detectable for 15 months, and the patient is in ongoing remission. One patient (patient 15) died in CR because of metabolic acidosis with no sign of lymphoma relapse. Table 1 summarizes the obtained data.
PCR for the Rearranged Immunoglobulin Heavy Chain VH The PCR technique for the rearranged immunoglobulin heavy chain VH may reveal a polyclonal pattern (Fig 1, lane 8), indicating a polyclonal B-cell infiltration, an oligoclonal B-cell proliferation (Fig 1, lane 5), or the presence of bi- or monoclonal B cells (Fig 1, lane 1). At diagnosis, the results were as follows: in 10 patients, a monoclonal band was detected. In one patient, a biclonal distribution of PCR bands was detected. In six patients, an oligoclonal pattern was shown. In three patients (patient nos. 3, 4, and 6) polyclonal PCR bands were determined in the Genescan analysis at diagnosis (Table 2).
During follow-up over a median time of 37 months (range, 5 to 69 months), biopsy samples were available in 18 of 20 patients. Two to eight consecutive samples (median, five samples) were analyzed in each patient. Three patients with polyclonal PCR bands at diagnosis remained polyclonal during follow-up. In 13 of 18 patients, gastric mucosa samples showed a polyclonal PCR during follow-up investigations (Fig 2).
One patient (patient 7) showed one monoclonal peak in the Genescan analysis, whereas the sequence analysis of this PCR fragment showed a polyclonal distribution of VH alleles and was considered polyclonal. The investigation of patient 20 revealed a persistence of the clonal (bi-triclonal) PCR bands. This patient did not respond to therapy and died of disease progression (Table 2). In the subgroup of eight patients with MZBCL (n = 4) and MZBCL with fractions of DLCL (n = 4), no patients revealed persisting clonality during a median follow-up of 48 months (range, 14 to 68 months).
V(D)J Sequences at Diagnosis
Sequence Analysis During Follow-Up After Treatment
Many authors believe that cure of H pylori infection has been established as first-line therapy for early gastric MZBCL of MALT type stage I E1.5,7,8,10,11,22 Nevertheless, we and others have reported the persistence of a monoclonal PCR band for the rearranged variable region of the immunoglobulin heavy chain gene during follow-up.9-12,16 This observation may point to resting lymphoma cells and a potential higher relapse risk. The present study was performed to investigate whether the finding of persisting monoclonal PCR bands is a common feature after lymphoma regression of gastric lymphomas induced by radiochemotherapy. We investigated the molecular follow-up in patients with gastric B-cell NHL at Ann Arbor stage I/II after radiochemotherapy by means of a PCR assay for the rearranged immunoglobulin heavy chain VH over a median follow-up time of 37 months (range, 5 to 69 months). Only one patient showed a persistence of clonal PCR bands, but this patient did not achieve CR and died because of disease progression. These results suggest that radiochemotherapy leads to a complete eradication of lymphoma cells in gastric lymphoma. In contrast, H pylori eradication therapy induces a minimal residual disease in approximately 45% to 50% of patients, possibly as a result of immunoregulation of the disease.9,10,16 Whether this is associated with a higher risk of relapse still remains unclear. Although MALT lymphoma cells show rather slow progression, relapses were observed after H pylori eradication. Thus lifelong endoscopic follow-up is indicated to detect early relapses, which could be treated with salvage therapy either via conventional radiotherapy23-25 or via therapy with anti-CD20 monoclonal antibody.26 In the present retrospective investigation, not only gastric MALT lymphoma patients were evaluated, but also patients with diffuse large B-cell lymphomas and patients with composite lymphomas consisting of low-grade MALT lymphomas and large-cell fractions. Thus all patients in this study and the patients investigated for minimal residual disease in other studies9-11,16 are not completely comparable. However, in the present study, four patients suffered from gastric MALT lymphomas and another four from low-grade MALT lymphomas with large-cell fractions. None of these eight patients revealed persisting clonality during follow-up. Because these patients are comparable to the patients analyzed after cure of H pylori infection,9-11,16 we believe the data suggest that chemoradiotherapy induces an improved clearing of residual gastric lymphoma cells as compared with H pylori eradication alone. Yahalom et al27 recently reported a series of nine patients with stage I/IIE MALT lymphoma receiving radiotherapy alone and showed, in seven of nine cases, an ongoing PCR monoclonality at a median follow-up time of 28 months. Because clone-specific primers were used for this PCR analysis, these results are not directly comparable to ours. Nevertheless, the patients we investigated received not only local therapy (ie, radiotherapy) but also chemotherapy. It seems possible that the systemic effect of chemotherapy leads to eradication of distantly residing lymphoma cells, which therefore are no longer contributing to a repopulating of the gastric mucosa by homing. As shown by Du et al,28 gastric MALT lymphoma cells preferentially disseminate to the marginal zone in case of splenic involvement, indicating their normal homing properties. In our study sequence, analyses were performed for the monoclonal immunoglobulin heavy chain fragment before therapy and during follow-up. The consecutive samples of one patient showed VH alleles that were completely unrelated to the initially detected allele. This may be caused by a heterogeneous distribution of two or even more lymphoma clones within one tumor, which were detected when the follow-up biopsy samples were taken from different areas. The follow-up samples in three patients showed identical allele-sequences. No further ongoing mutations were observed. The occurrence of somatic hypermutations may be interpreted as a marker for antigen selection, because mutations in the immunoglobulin receptor gene may lead to a better antigen recognition. Ongoing mutations of the immunoglobulin receptor gene were described in samples of patients with persisting monoclonal PCR bands after H pylori eradication therapy.12,15 The absence of ongoing mutations in patient's samples after chemotherapy and irradiation may point to a less important influence of immunoregulation for the eradication of lymphoma cells after conventional therapy. Whether this is necessarily of benefit for the patients remains unclear at present. In summary, conservative therapy of gastric lymphomas involving chemotherapy and radiation therapy leads to clearing of monoclonal B cells in all responding patients. This is in contrast to therapy of curing H pylori infection, which frequently shows monoclonal B cells as a sign for ongoing minimal residual disease.9,10,16
The authors indicated no potential conflicts of interest.
Supported by the Deutsche Krebshilfe (grant No. 70-2251, Ne1). Authors' disclosures of potential conflicts of interest are found at the end of this article.
1. Isaacson PG, Wright DH: Malignant lymphoma of mucosa associated lymphoid tissue. Cancer 52:1410-1416, 1983[CrossRef][Medline] 2. Wotherspoon A, Ortiz-Hidalgo C, Falzon MR, et al: Helicobacter pylori-associated gastritis and primary gastric lymphoma. Lancet 338:1175-1176, 1991[CrossRef][Medline] 3. Hussell T, Isaacson PG, Crabtree JE, et al: Immunoglobulin specificity of low-grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. Am J Pathol 142:285-292, 1993[Abstract] 4. Hussell T, Isaacson PG, Crabtree JE, et al: Helicobacter pylori specific tumor infiltrating T-cells provide contact dependent help for the growth of malignant B-cells in low-grade gastric MALT-lymphoma of mucosa associated lymphoid tissue. J Pathol 178:122-127, 1996[CrossRef][Medline] 5. Wotherspoon A, Doglinoni C, Diss TC, et al: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575-577, 1993[CrossRef][Medline] 6. Stolte M, Eidt S: Healing gastric MALT-lymphomas by eradicating H. pylori. Lancet 342:568, 1993[CrossRef][Medline] 7. Bayerdörffer E, Neubauer A, Rudolph B, et al: Regression of primary lymphoma of the mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 345:1591-1594, 1995[CrossRef][Medline]
8. Roggero E, Zucca E, Pinotti G, et al: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122:767-769, 1995
9. Savio A, Franzin G, Wotherspoon A, et al: Diagnosis and posttreatment follow-up of Helicobacter pylori positive gastric lymphoma of mucosa-associated lymphoid tissue: Histology, polymerase chain reaction, or both? Blood 87:1255-1260, 1996
10. Francesco B, Conconi A, Capella C, et al: Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: Early analysis of the Ly03 cooperative trial. Blood 99:2541-2544, 2002
11. Neubauer A, Thiede C, Morgner A, et al: Cure of Helicobacter pylori infection and duration of remission of low-grade gastric MALT-lymphoma. J Natl Cancer Inst 89:1350-1355, 1997
12. Thiede C, Alpen B, Morgner A, et al: Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 16:3822-3831, 1998 13. Rajewsky K: Clonal selection and learning in the antibody system. Nature 381:751-758, 1996[CrossRef][Medline]
14. Qin Y, Greiner A, Trunk MJF, et al: Somatic hypermutation in low-grade mucosa-associated lymphoid tissue-type B-cell lymphoma. Blood 86:3528-3534, 1995 15. Du M, Diss TC, Xu C, et al: Ongoing mutations in MALT-lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia 10:1190-1197, 1996[Medline]
16. Thiede C, Wündisch T, Alpen B, et al: Long term persistence of monoclonal B-cells after cure of Helicobacter pylori infection and obtaining complete histological remission in gastric mucosa associated lymphoid tissue (MALT) B cell lymphoma. J Clin Oncol 19:1600-1609, 2001 17. Sonnen R, Kuse R: Langzeitergebnisse der Behandlung hochmaligner Non-Hodgkin-Lymphome im hohen Lebensalter (70 Jahre und älter). Dtsch Med Wschr 123:205-211, 1998[Medline] 18. Diss TC, Peng H, Wotherspoon AC, et al: Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J Pathol 169:291-295, 1993[CrossRef][Medline] 19. Neubauer A, Neubauer B, Liu E: Polymerase chain reaction based assay to detect allelic loss in human DNA: Loss of beta-interferon gene in chronic myelogeneous leukemia. Nucleic Acids Res 18:993-998, 1990 20. Tomlinson IM, Walter G, Marks JD, et al: The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. Academic Press 776-798, 1992 21. Cook GP, Tomlinson IM, Walter G, et al: A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. Nat Genet 7:162-168, 1994[CrossRef][Medline] 22. Thiede C, Morgner A, Alpen B, et al: What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT-lymphoma? Gastroenterology 113:S61-S64, 1997 (suppl 6)[Medline] 23. Schechter NR, Portlock CS, Yahalom J: Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16:1916-1921, 1998[Abstract]
24. Koch P, del Valle F, Berdel WE, et al: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 19:3861-3873, 2001
25. Koch P, del Valle F, Berdel WE, et al: Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphomaResults of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 19:3874-3883, 2001 26. Visconti JL, Petruska PJ, Dunphy CH, et al: Rituximab in the treatment of gastrointestinal mucosa-associated lymphoid tissue lymphoma. Blood 94:270b, 1999 (suppl I, abstr 4418) 27. Noy A, Yahalom J, Zaretsky L, et al: Clonal specific PCR detects clonal cells after radiation therapy for early stage gastric MALT-lymphoma. Blood 100:772a, 2002 (abstr 3052)
28. Du MQ, Peng HZ, Dogan A, et al: Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone. Blood 90:4071-4077, 1997 Submitted August 27, 2003; accepted April 29, 2004.
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|